Key Highlights
- Kevin Franck, a seasoned expert in audiology and inner-ear therapies, joins Otolith Labs to lead clinical and regulatory strategies.
- Otolith Labs is set to revolutionize vestibular disorder treatment with FDA-designated breakthrough devices.
- Franck will focus on FDA submissions and market strategies for new treatments targeting millions with vestibular disorders.
Source: Business Wire
Notable Quotes
- “We’re thrilled Kevin is completing our executive team with his decades of clinical experience. His wealth of knowledge and relationships in the ENT community will be critical in developing partnerships with key opinion leaders and clinicians in the field,” – Sam Owen, CEO and Founder at Otolith Labs
- “Otolith’s breakthrough technology introduces something truly new for clinicians to bring to patients with chronic vertigo, where there is little else to offer. I am excited to join Otolith and help foster much needed innovation in the ENT space,” – Dr. Kevin Franck, Chief Clinical Officer at Otolith Labs
SoHC's Take
Kevin Franck’s appointment as Chief Clinical Officer at Otolith Labs is a strategic move that bolsters the company’s position at the forefront of medical technology for vestibular disorders. His extensive background in audiology and leadership roles across notable organizations in the ENT space is invaluable as Otolith prepares for FDA submissions and market introduction of its groundbreaking devices. Franck’s vision for leveraging technology to improve quality of life for millions aligns perfectly with Otolith’s innovative approach, marking a promising next chapter for the company.
